Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia von Zeidner, Joshua F, Karp, Judith E

Volltext

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML von Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel

Volltext

Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia von Rutella, Sergio, Vadakekolathu, Jayakumar, Mazziotta, Francesco, Reeder, Stephen, Yau, Tung-On, Mukhopadhyay, Rupkatha, Dickins, Benjamin, Altmann, Heidi, Kramer, Michael, Knaus, Hanna A, Blazar, Bruce R, Radojcic, Vedran, Zeidner, Joshua F, Arruda, Andrea, Wang, Bofei, Abbas, Hussein A, Minden, Mark D, Tasian, Sarah K, Bornhäuser, Martin, Gojo, Ivana, Luznik, Leo

Volltext

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine plus Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia von Zeidner, Joshua F., Lee, Daniel J., Frattini, Mark, Fine, Gil D., Costas, Judy, Kolibaba, Kathryn, Anthony, Stephen P., Bearss, David, Smith, B. Douglas

Volltext

Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes von Zeidner, Joshua F, Mazerolle, Flora, Norton, Jonathan, Regnault, Antoine, Kristo, Fjoralba, Romero, Heather, Fram, Robert J, Faller, Douglas V, Dalal, Mehul, Ades, Lionel, Sekeres, Mikkael A

Volltext

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype? von Snow, Anson, Zeidner, Joshua F.

Volltext

Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML von Zeidner, Joshua F.

Volltext

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease von Johnson, Steven M., Haberberger, James, Galeotti, Jonathan, Ramkissoon, Lori, Coombs, Catherine C., Richardson, Daniel R., Foster, Matthew C., Duncan, Daniel, Zeidner, Joshua F., Ferguson, Naomi L., Montgomery, Nathan D.

Volltext

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute my... von Zeidner, Joshua F., Foster, Matthew C., Blackford, Amanda L., Litzow, Mark R., Morris, Lawrence E., Strickland, Stephen A., Lancet, Jeffrey E., Bose, Prithviraj, Levy, M. Yair, Tibes, Raoul, Gojo, Ivana, Gocke, Christopher D., Rosner, Gary L., Little, Richard F., Wright, John J., Doyle, L. Austin, Smith, B. Douglas, Karp, Judith E.

Volltext

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms von Zeidner, Joshua F, Karp, Judith E, Blackford, Amanda L, Smith, B Douglas, Gojo, Ivana, Gore, Steven D, Levis, Mark J, Carraway, Hetty E, Greer, Jacqueline M, Ivy, S Percy, Pratz, Keith W, McDevitt, Michael A

Volltext

Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes von Gerber, Jonathan M, Zeidner, Joshua F, Morse, Sarah, Blackford, Amanda L, Perkins, Brandy, Yanagisawa, Breann, Zhang, Hao, Morsberger, Laura, Karp, Judith, Ning, Yi, Gocke, Christopher D, Rosner, Gary L, Smith, B Douglas, Jones, Richard J

Volltext

TP53 or Not TP53: That Is the Question von Green, Steven D, Zeidner, Joshua F

Volltext

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study von Sallman, David A, Al Malki, Monzr M, Asch, Adam S, Wang, Eunice S, Jurcic, Joseph G, Bradley, Terrence J, Flinn, Ian W, Pollyea, Daniel A, Kambhampati, Suman, Tanaka, Tiffany N, Zeidner, Joshua F, Garcia-Manero, Guillermo, Jeyakumar, Deepa, Komrokji, Rami, Lancet, Jeffrey, Kantarjian, Hagop M, Gu, Lin, Zhang, Yajia, Tan, Anderson, Chao, Mark, O'Hear, Carol, Ramsingh, Giridharan, Lal, Indu, Vyas, Paresh, Daver, Naval G

Volltext

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML von Swords, Ronan T., Coutre, Steven, Maris, Michael B., Zeidner, Joshua F., Foran, James M., Cruz, Jose, Erba, Harry P., Berdeja, Jesus G., Tam, Wayne, Vardhanabhuti, Saran, Pawlikowska-Dobler, Iwona, Faessel, Hélène M., Dash, Ajeeta B., Sedarati, Farhad, Dezube, Bruce J., Faller, Douglas V., Savona, Michael R.

Volltext

Philadelphia Chromosome‐positive Acute Myeloid Leukemia With e1a3 BCR‐ABL1 Fusion Transcript von Sheets, Julia W., Eulitt, Patrick, He, Rong, Olteanu, Horatiu, Coombs, Catherine C., Foster, Matthew C., Montgomery, Nathan D., Zeidner, Joshua F.

Volltext

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia von Zeidner, Joshua F., Lin, Tara L., Vigil, Carlos E., Fine, Gil, Yair Levy, M., Nazha, Aziz, Esteve, Jordi, Lee, Daniel J., Yee, Karen, Dalovisio, Andrew, Wang, Eunice S., Bergua Burgues, Juan M., Schriber, Jeffrey, Litzow, Mark R., Frankfurt, Olga, Castillo, Teresa Bernal Del, Bhatt, Vijaya Raj, Bhatnagar, Bhavana, Mehta, Priyanka, Dillon, Richard, Vicente, Maria Vidriales, Anthony, Stephen, Bearss, David, Montesinos, Pau, Douglas Smith, B.

Volltext

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy von Hu, Quanyin, Sun, Wujin, Wang, Jinqiang, Ruan, Huitong, Zhang, Xudong, Ye, Yanqi, Shen, Song, Wang, Chao, Lu, Weiyue, Cheng, Ke, Dotti, Gianpietro, Zeidner, Joshua F., Wang, Jun, Gu, Zhen

Volltext

Acute Myeloid Leukemia with Co‐mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia von Johnson, Steven M., Richardson, Daniel R., Galeotti, Jonathan, Esparza, Sonia, Zhu, Anqi, Fedoriw, Yuri, Weck, Karen E., Foster, Matthew C., Coombs, Catherine C., Zeidner, Joshua F., Montgomery, Nathan D.

Volltext

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure von Zeidan, Amer M, Knaus, Hanna A, Robinson, Tara M, Towlerton, Andrea M H, Warren, Edus H, Zeidner, Joshua F, Blackford, Amanda L, Duffield, Amy S, Rizzieri, David, Frattini, Mark G, Levy, Yair M, Schroeder, Mark A, Ferguson, Anna, Sheldon, Katherine E, DeZern, Amy E, Gojo, Ivana, Gore, Steven D, Streicher, Howard, Luznik, Leo, Smith, B Douglas

Volltext

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results von Daver, Naval G, Vyas, Paresh, Kambhampati, Suman, Al Malki, Monzr M, Larson, Richard A, Asch, Adam S, Mannis, Gabriel, Chai-Ho, Wanxing, Tanaka, Tiffany N, Bradley, Terrence J, Jeyakumar, Deepa, Wang, Eunice S, Sweet, Kendra, Kantarjian, Hagop M, Garcia-Manero, Guillermo, Komrokji, Rami, Xing, Guan, Ramsingh, Giridharan, Renard, Camille, Zeidner, Joshua F, Sallman, David A

Volltext